Rucaparib is now approved for BRCA mutation-associated mCRPC patients post-androgen receptor therapy, without prior chemotherapy requirement. The TRITON3 trial showed significant improvement in ...

Early treatment intensification with ADT and ARPIs is now standard for mCSPC, with patient-specific factors guiding therapy selection. Enzalutamide, apalutamide, abiraterone, and darolutamide are key ...

NAI plus BCG demonstrates significant disease-specific survival, progression-free survival, and cystectomy avoidance in BCG-unresponsive high-grade papillary-only NMIBC at 36 months. The treatment is ...

Flibanserin (Addyi) is now approved for treating HSDD in postmenopausal women, expanding its previous indication for premenopausal women. The FDA's priority review designation for flibanserin ...

The FDA approved niraparib with abiraterone acetate and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer based on the AMPLITUDE trial results. The trial demonstrated ...

Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...

Experts recommend removing unsupported prostate cancer warnings from TRT labels and aligning indications with professional guidelines. Testosterone's Schedule III classification creates barriers to ...

"The addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival without adversely affecting patient-reported outcomes,” said ...

IsoPSA, a blood-based test, aids in diagnosing high-grade prostate cancer by analyzing PSA protein structural variants. FDA approval was based on a large-scale, prospective study and other validation ...

Fosfomycin received FDA approval for complicated urinary tract infections, demonstrating noninferiority to piperacillin/tazobactam in the ZEUS trial. The FDA removed ...

"Based on the code description, we recommend basing the code selection on the documentation and the effort required to complete the service, and not the number of foreign bodies removed from the ...

Individualized hormone therapy duration for prostate cancer can reduce unnecessary treatment and side effects, based on cancer risk. Meta-analysis of 10,266 men showed diminishing benefits of ADT ...